HPMA copolymerAnticancer Agents Currently in Human Trials

Presently there are seven polymer-drug conjugates which have entered Phase I/II clinical trials as anti-cancer agents in the U.K (five of which are HPMA copolymer-drug conjugates). These include N-(2-hydroxy-propyl)methacrylamide (HPMA) copolymer doxorubicin (PK1, FCE 28068), HPMA copolymer-paclitaxel (PNU 166945), HPMA copolymer-camptothecin, PEG-camptothecin, poly(glutamic acid)-paclitaxel, HPMA copolymer-platinate (AP 5280), and HPMA copolymer-doxorubicin conjugates bearing galactosamine (PK2). The rapid proliferation of HPMA copolymer anti-cancer agents is evidence of the promising potential of HPMA copolymer carried agents.

0 0

Post a comment